Labcorp Holdings Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Labcorp Holdings de 19.1% y 3.7% por año respectivamente. Se prevé que el BPA crezca en un 21.1% al año. Se espera que la rentabilidad financiera sea de 15.8% en 3 años.

Información clave

19.2%

Tasa de crecimiento de los beneficios

21.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	19.3%
Tasa de crecimiento de los ingresos	4.8%
Rentabilidad financiera futura	16.0%
Cobertura de analistas	Good
Última actualización	23 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why It's Unlikely That Laboratory Corporation of America Holdings' (NYSE:LH) CEO Will See A Pay Rise This Year

May 08

Laboratory Corporation of America Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72

Apr 30

Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72

Apr 15

Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark

Apr 06

Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear

Apr 01

Laboratory Corporation of America Holdings (NYSE:LH) Will Pay A Dividend Of $0.72

Feb 25

We Think You Can Look Beyond Laboratory Corporation of America Holdings' (NYSE:LH) Lackluster Earnings

Feb 22

An Intrinsic Calculation For Laboratory Corporation of America Holdings (NYSE:LH) Suggests It's 48% Undervalued

Feb 21

Laboratory Corporation of America Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72

Jan 31

Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly

Jan 30

Laboratory Corporation of America Holdings' (NYSE:LH) Dividend Will Be $0.72

Jan 15

Some Shareholders Feeling Restless Over Laboratory Corporation of America Holdings' (NYSE:LH) P/E Ratio

Jan 05

Laboratory Corporation: Multiple Updates, Same Investment Conclusion

Dec 02

Laboratory Corp.: Rate On Capital Deployed Contracting, Hold

Sep 14

Laboratory Corporation: Trying To Create Value By Spinning Out Fortrea

Jul 05

Newsflash: Laboratory Corporation of America Holdings (NYSE:LH) Analysts Have Been Trimming Their Revenue Forecasts

Jul 04

Are Investors Undervaluing Laboratory Corporation of America Holdings (NYSE:LH) By 43%?

Jun 23

Laboratory Corporation: Predictability Of Cash Flows Less Visible

Jun 21

Is It Too Late To Consider Buying Laboratory Corporation of America Holdings (NYSE:LH)?

May 26

Laboratory Corporation of America Holdings' (NYSE:LH) Returns On Capital Are Heading Higher

Mar 16

Laboratory Corporation of America Holdings (NYSE:LH) Shares Could Be 32% Below Their Intrinsic Value Estimate

Mar 02

Laboratory Corporation of America Non-GAAP EPS of $4.14 in-line, revenue of $3.7B misses by $40M, introduces FY23 outlook

Feb 16

Previsiones de crecimiento de beneficios e ingresos

NYSE:LH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	14,325	1,176	1,441	1,937	10
12/31/2025	13,708	1,080	1,098	1,588	15
12/31/2024	12,965	958	990	1,455	15
6/30/2024	12,488	450	962	1,496	N/A
3/31/2024	12,300	399	767	1,276	N/A
12/31/2023	12,162	379	874	1,328	N/A
9/30/2023	12,058	583	1,012	1,397	N/A
6/30/2023	11,868	677	1,008	1,372	N/A
3/31/2023	11,757	789	1,122	1,513	N/A
12/31/2022	11,864	1,002	1,417	1,847	N/A
9/30/2022	12,990	1,518	1,415	1,895	N/A
6/30/2022	14,186	1,829	1,788	2,303	N/A
3/31/2022	15,104	2,028	1,826	2,308	N/A
12/31/2021	13,136	2,195	2,597	3,018	N/A
9/30/2021	16,555	2,763	2,777	3,187	N/A
6/30/2021	16,388	2,879	2,836	3,206	N/A
3/31/2021	15,316	2,643	2,719	3,089	N/A
12/31/2020	13,979	1,556	1,754	2,135	N/A
9/30/2020	12,442	845	1,520	1,931	N/A
6/30/2020	11,475	362	1,174	1,600	N/A
3/31/2020	11,587	321	1,070	1,483	N/A
12/31/2019	11,555	824	1,045	1,445	N/A
9/30/2019	11,389	755	967	1,361	N/A
6/30/2019	11,292	853	758	1,158	N/A
3/31/2019	11,276	896	890	1,292	N/A
12/31/2018	11,333	884	926	1,305	N/A
9/30/2018	11,291	1,414	1,030	1,384	N/A
6/30/2018	11,081	1,266	1,198	1,529	N/A
3/31/2018	10,743	1,217	N/A	1,452	N/A
12/31/2017	10,308	1,227	N/A	1,498	N/A
9/30/2017	9,951	724	N/A	1,382	N/A
6/30/2017	9,702	732	N/A	1,235	N/A
3/31/2017	9,556	751	N/A	1,274	N/A
12/31/2016	9,553	712	N/A	1,197	N/A
9/30/2016	9,295	658	N/A	1,112	N/A
6/30/2016	9,192	633	N/A	1,150	N/A
3/31/2016	9,029	599	N/A	1,197	N/A
12/31/2015	8,506	438	N/A	982	N/A
9/30/2015	7,774	447	N/A	812	N/A
6/30/2015	7,056	430	N/A	699	N/A
3/31/2015	6,353	401	N/A	510	N/A
12/31/2014	6,012	511	N/A	739	N/A
9/30/2014	5,936	518	N/A	774	N/A
6/30/2014	5,846	529	N/A	833	N/A
3/31/2014	5,798	540	N/A	763	N/A
12/31/2013	5,808	574	N/A	819	N/A
9/30/2013	5,777	568	N/A	824	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (19.1% al año) de LH es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (19.1% al año) de LH crezcan más rápidamente que el mercado US (14.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de LH crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (3.7% al año) de LH crezcan más despacio que el mercado de US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.7% al año) de LH crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de LH sea baja dentro de 3 años (15.8%).

Labcorp Holdings Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Consensus revenue estimates decrease by 17%

Consensus revenue estimates fall by 14%

Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023

Recent updates

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.

When Should You Buy Labcorp Holdings Inc. (NYSE:LH)?

Laboratory Corporation: Difficult To Eye Long-Term Compounding Ability

Upcoming dividend of US$0.72 per share

CFO & Executive VP recently sold US$3.4m worth of stock

CFO & Executive VP notifies of intention to sell stock

Insider recently sold US$2.8m worth of stock

Insider notifies of intention to sell stock

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024

Investors Still Waiting For A Pull Back In Labcorp Holdings Inc. (NYSE:LH)

Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024

Laboratory Corporation: Limited Upside Visibility, Reiterate Hold

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials

When Should You Buy Labcorp Holdings Inc. (NYSE:LH)?

Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio

Upcoming dividend of US$0.72 per share

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy

Here's Why It's Unlikely That Laboratory Corporation of America Holdings' (NYSE:LH) CEO Will See A Pay Rise This Year

Laboratory Corporation of America Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Dividend of US$0.72 announced

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Executive VP notifies of intention to sell stock

Labcorp Launches Weight Loss Management Testing Solutions

Laboratory Corporation of America Holdings (NYSE:LH) Will Pay A Dividend Of $0.72

CFO & Executive VP recently sold US$4.4m worth of stock

We Think You Can Look Beyond Laboratory Corporation of America Holdings' (NYSE:LH) Lackluster Earnings

An Intrinsic Calculation For Laboratory Corporation of America Holdings (NYSE:LH) Suggests It's 48% Undervalued

Upcoming dividend of US$0.72 per share

Full year 2023 earnings: EPS misses analyst expectations

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Laboratory Corporation of America Holdings' (NYSE:LH) Dividend Will Be $0.72

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Some Shareholders Feeling Restless Over Laboratory Corporation of America Holdings' (NYSE:LH) P/E Ratio

Laboratory Corporation: Multiple Updates, Same Investment Conclusion

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Upcoming dividend of US$0.72 per share at 1.5% yield

New minor risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Laboratory Corp.: Rate On Capital Deployed Contracting, Hold

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations